Palisade Bio is a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, with a lead candidate designed to deliver active drug locally to the colon where bacterial enzymes activate it, thereby reducing systemic exposure and tolerability issues associated with existing treatments. The company targets ulcerative colitis, Crohn's disease, and fibrostenosing Crohn's disease—markets representing substantial unmet medical need among patients with inadequate response to current therapies, drug intolerance, or limited treatment options. Palisade operates without commercial infrastructure, relying on contract manufacturers for drug supply and planning to commercialize through internal build-out and/or partnerships upon regulatory approval, while holding exclusive worldwide rights to its lead program through a licensing agreement with milestone and royalty obligations.